Literature DB >> 31322989

Standardizing Febrile Neutropenia Management: Antimicrobial Stewardship in the Hematologic Malignancy Population.

John C O'Horo1,2, Jasmine R Marcelin1, Omar M Abu Saleh1, Amelia K Barwise1,2, Patricia M Odean1, Christina G Rivera1, Aaron J Tande1, John W Wilson1, Douglas R Osmon1, Pritish K Tosh1.   

Abstract

Patients with febrile neutropenia (FN) often are subject to antibiotic and diagnostic test overuse. We sought to improve appropriate use of antimicrobials and diagnostic tests for patients with FN. We used a blended quality approach with Lean Six Sigma tools and iterative improvement of a clinical decision aid to guide providers through empirical antimicrobial selection and diagnostic evaluation of patients with FN during a yearlong period. We evaluated the incidence of nonadherence to best practice before, during, and after rollout of a clinical decision aid in conjunction with an educational initiative. At baseline, 71% of patients with FN had at least one critical deviation from best practice. During the project, the percentage decreased to 27.3%; 4 months after the project was completed, the percentage was 33.3% (P = .04). A clinical decision aid can improve adherence to best practices for the empirical management of FN.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31322989      PMCID: PMC6743219          DOI: 10.1200/JOP.18.00775

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  17 in total

1.  Febrile neutropenia in EDs: the role of an electronic clinical practice guideline.

Authors:  Charles Lim; Jaime Bawden; Andrew Wing; Cristina Villa-Roel; David P Meurer; Michael J Bullard; Brian H Rowe
Journal:  Am J Emerg Med       Date:  2010-10-27       Impact factor: 2.469

2.  Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia.

Authors:  Regis G Rosa; Luciano Z Goldani
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.

Authors:  J Klastersky; J de Naurois; K Rolston; B Rapoport; G Maschmeyer; M Aapro; J Herrstedt
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

4.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Leon E Cosler; Gary H Lyman
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

5.  Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides.

Authors:  M Nucci; M Landau; F Silveira; N Spector; W Pulcheri
Journal:  Infect Control Hosp Epidemiol       Date:  2001-10       Impact factor: 3.254

6.  Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.

Authors:  Lenaïg Le Clech; Jean-Philippe Talarmin; Marie-Anne Couturier; Jean-Christophe Ianotto; Christophe Nicol; Ronan Le Calloch; Stéphanie Dos Santos; Pascal Hutin; Didier Tandé; Virginie Cogulet; Christian Berthou; Gaëlle Guillerm
Journal:  Infect Dis (Lond)       Date:  2018-02-16

7.  Emergency Department Management of Patients With Febrile Neutropenia: Guideline Concordant or Overly Aggressive?

Authors:  Christopher W Baugh; Thomas J Wang; Jeffrey M Caterino; Olesya N Baker; Gabriel A Brooks; Audrey C Reust; Daniel J Pallin
Journal:  Acad Emerg Med       Date:  2017-01       Impact factor: 3.451

8.  Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes.

Authors:  Jason D Wright; Alfred I Neugut; Cande V Ananth; Sharyn N Lewin; Elizabeth T Wilde; Yu-Shiang Lu; Thomas J Herzog; Dawn L Hershman
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

9.  Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes.

Authors:  J Zuckermann; L B Moreira; P Stoll; L M Moreira; R S Kuchenbecker; C A Polanczyk
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673

10.  Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study.

Authors:  Regis G Rosa; Luciano Z Goldani; Rodrigo P dos Santos
Journal:  BMC Infect Dis       Date:  2014-05-23       Impact factor: 3.090

View more
  2 in total

1.  Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States.

Authors:  Jason N Barreto; Samuel L Aitken; Elizabeth M Krantz; Jerod L Nagel; Sanjeet S Dadwal; Susan K Seo; Catherine Liu
Journal:  Open Forum Infect Dis       Date:  2022-02-04       Impact factor: 4.423

2.  Aminoglycoside use in paediatric febrile neutropenia - Outcomes from a nationwide prospective cohort study.

Authors:  Brendan J McMullan; Gabrielle M Haeusler; Lisa Hall; Louise Cooley; Andrew J Stewardson; Christopher C Blyth; Cheryl A Jones; Pamela Konecny; Franz E Babl; Françoise Mechinaud; Karin Thursky
Journal:  PLoS One       Date:  2020-09-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.